Deerfield Management ALDX Position
ExitedDeerfield Management exited their position in Aldeyra Therapeutics Inc. (ALDX) in Q2 2025, after holding the stock for 2 quarters.
The position was first reported in Q1 2025 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds ALDX.
There is an upcoming Phase 3 readout for ICM ADX-2191 injection in 259 days (Dec 31, 2026), making the timing of Deerfield's position particularly relevant.
Short interest stands at 11.0% of float with 5.3 days to cover, indicating significant bearish positioning against the stock.
About Aldeyra Therapeutics Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Full company profile →Short Interest
11.0%
5.3 days to cover
Deerfield Management ALDX Position History
Frequently Asked Questions
Does Deerfield Management own ALDX?
No. Deerfield Management exited their position in Aldeyra Therapeutics Inc. (ALDX) in Q2 2025. They previously held the stock for 2 quarters.
How many hedge funds own ALDX?
1 specialist biotech hedge fund currently holds ALDX, including Perceptive Advisors. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ALDX?
Deerfield Management's position in ALDX was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ALDX position increasing or decreasing?
Deerfield Management completely exited their ALDX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALDXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →